PBYI - Puma Biotechnology Inc
IEX Last Trade
2.51
0.060 2.390%
Share volume: 328,427
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$2.45
0.06
2.45%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-03 | 2023-03-02 | 2023-05-04 | 2023-08-03 | 2023-11-02 | 2024-02-29 | 2024-05-02 | 2024-08-01 | |
| Assets | |||||||||
| Total Assets | 198.770 M | 222.059 M | 196.257 M | 200.494 M | 203.605 M | 230.528 M | 214.149 M | 205.002 M | |
| Current Assets | 122.353 M | 134.281 M | 111.753 M | 118.552 M | 125.354 M | 156.185 M | 143.026 M | 137.720 M | |
| Inventories | 5.452 M | 4.526 M | 3.891 M | 7.631 M | 5.679 M | 7.080 M | 7.100 M | 9.049 M | |
| Other Current Assets | 10.911 M | 8.331 M | 5.481 M | 5.192 M | 5.672 M | 5.329 M | 4.179 M | 3.734 M | |
| Short Term Investments | 10.911 M | 8.331 M | 5.481 M | 5.192 M | 5.672 M | 5.329 M | 4.179 M | 3.734 M | |
| Total Receivables | 28.030 M | 40.350 M | 31.164 M | 31.290 M | 28.974 M | 47.837 M | 24.584 M | 28.105 M | |
| Current Cash | 77.960 M | 81.074 M | 71.217 M | 74.439 M | 85.029 M | 95.939 M | 107.163 M | 96.832 M | |
| Total Non-current Assets | 76.417 M | 87.778 M | 84.504 M | 81.942 M | 78.251 M | 74.343 M | 71.123 M | 67.282 M | |
| Property Plant Equipment | 1.282 M | 1.146 M | 1.019 M | 977.000 K | 907.000 K | 855.000 K | 757.000 K | 680.000 K | |
| Other Assets | 377.000 K | 2.069 M | 2.069 M | 2.720 M | 2.908 M | 2.734 M | 2.816 M | 2.279 M | |
| Intangible Assets | 60.114 M | 70.610 M | 68.175 M | 65.740 M | 63.305 M | 60.871 M | 58.436 M | 56.001 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 198.770 M | 222.059 M | 196.257 M | 200.494 M | 203.605 M | 230.528 M | 214.149 M | 205.002 M | |
| Total liabilities | 176.615 M | 200.451 M | 170.410 M | 170.095 M | 164.863 M | 177.086 M | 163.167 M | 156.493 M | |
| Total current liabilities | 59.987 M | 77.484 M | 48.188 M | 60.287 M | 67.362 M | 99.382 M | 98.191 M | 104.296 M | |
| Accounts Payable | 14.927 M | 6.440 M | 8.589 M | 7.795 M | 5.061 M | 6.889 M | 8.964 M | 13.500 M | |
| Other liabilities | 5.711 M | 12.826 M | 12.884 M | 12.663 M | 12.571 M | 5.011 M | 4.547 M | 4.098 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 11.332 M | 22.664 M | 33.997 M | 45.329 M | 45.329 M | |
| Long term debt | 97.994 M | 98.307 M | 98.623 M | 87.622 M | 76.634 M | 65.659 M | 54.691 M | 43.735 M | |
| Other liabilities | 5.711 M | 12.826 M | 12.884 M | 12.663 M | 12.571 M | 5.011 M | 4.547 M | 4.098 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 22.155 M | 21.608 M | 25.847 M | 30.399 M | 38.742 M | 53.442 M | 50.982 M | 48.509 M | |
| Common stock | 45.568 M | 45.864 M | 46.636 M | 46.759 M | 47.520 M | 47.622 M | 48.189 M | 48.292 M | |
| Retained earnings | -1.361 B | -1.367 B | -1.365 B | -1.363 B | -1.357 B | -1.345 B | -1.350 B | -1.355 B |